Neuroendocrine

EAQ222CD ***NON-METASTATIC COHORT CLOSED TO ACCRUAL EFFECTIVE 1/13/26****

Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients

---

EAY191-N5 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)

A Randomized Trial of Neratinib, a Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors. A ComboMATCH Treatment Trial

---

EAY191 (ComboMATCH) **If biopsy needed, TBD at MBMC**

Molecular Analysis for Combination Therapy Choice

---

A021901

Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors

---

ALLIANCE A212102 **AT MBMC ONLY** ***Participant Engagement Portal (PEP) is Closed to New Patient Registration as of 9/15/25*** **As of 8/1/23 the following Healthy Control Cohorts are Open (all others are Closed as of 2/22/23): Non-White Male Participants Age 60 or More Without Cancer Diagnosis and Non-White Male Participants Under Age 60 Without Cancer Diagnosis** **Effective with the release of Update #02, enrollment to the thyroid, melanoma, and sarcoma cancer cohorts has been closed.**

Blinded Reference Set For Multicancer Early Detection Blood Tests

---